Page last updated: 2024-08-26

artenimol and Carcinoma, Lewis Lung

artenimol has been researched along with Carcinoma, Lewis Lung in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Chen, J; Li, Y; Liu, W; Tang, J; Wang, Y; Xiao, X; Yang, J; Yue, F; Zhang, Y1
Chen, X; Han, N; Hu, J; Li, LG; Li, QR; Li, TF; Peng, XC; Wang, MF; Xie, ZX; Xu, HZ; Xu, X; Yang, XX; Yang, ZY; Yu, TT1
Jin, Z; Li, Y; Wang, H; Wang, Y; Xiao, X; Yang, J; Yue, F; Zhang, Y; Zhou, Q; Zhou, S1
Dai, L; Lei, J; Li, C; Liu, J; Liu, K; Wang, L1
Li, A; Lou, XE; Wang, Z; Zhang, JL; Zhou, HJ1

Other Studies

5 other study(ies) available for artenimol and Carcinoma, Lewis Lung

ArticleYear
Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway.
    International immunopharmacology, 2022, Volume: 103

    Topics: Animals; Antineoplastic Agents; Artemisinins; Carcinogenesis; Carcinoma, Lewis Lung; Cell Differentiation; Cytokines; Mice; Mice, Inbred C57BL; Oncogene Protein v-akt; Signal Transduction; Th1 Cells; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Tumor-Associated Macrophages

2022
Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 112

    Topics: Animals; Carcinoma, Lewis Lung; DNA Damage; Endoplasmic Reticulum Stress; Ferroptosis; Immunotherapy; Lung Neoplasms; Mice; Tumor Microenvironment

2023
Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
    European journal of pharmacology, 2021, Oct-15, Volume: 909

    Topics: Animals; Apoptosis; Artemisinins; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Network Pharmacology; Protein Interaction Maps; Signal Transduction; TOR Serine-Threonine Kinases

2021
Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate.
    Scientific reports, 2016, 07-05, Volume: 6

    Topics: A549 Cells; Animals; Antineoplastic Agents; Artemisinins; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Hydrolysis; Inhibitory Concentration 50; Ligands; Mice; Nanoparticles; Neoplasm Transplantation; Particle Size; Polyethylene Glycols; Receptors, Transferrin; Solubility; Tissue Distribution; Transferrin; Xenograft Model Antitumor Assays

2016
Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Carcinoma, Lewis Lung; Cell Cycle; Cell Proliferation; Cell Survival; Cisplatin; Cyclophosphamide; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Random Allocation; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2010